Repros Therapeutics Inc logo

RPRX - Repros Therapeutics Inc Share Price

$41.98 0.7  1.7%

Last Trade - 18/09/20

Sector
Healthcare
Size
Large Cap
Market Cap £19.73bn
Enterprise Value £25.78bn
Revenue £1.50bn
Position in Universe 382nd / 6396
Bullish
Bearish
Unlock RPRX Revenue
Momentum
Relative Strength (%)
1m -3.56%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 1,598 1,795 1,814 +6.6%
+19.0 +70.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Royalty Pharma plc revenues increased 13% to $1.01B. Net income applicable to common stockholders decreased 94% to $33.5M. Revenues reflect Financial Royalty Assets increase of 17% to $937M. Net income was offset by Provision for changes in expected cash f increase from $22.2M to $135.3M (expense), General and administrative expenses increase of 48% to $80.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RPRX
Graphical History

Revenue

RPRX Revenue Unlock RPRX Revenue

Net Income

RPRX Net Income Unlock RPRX Revenue

Normalised EPS

RPRX Normalised EPS Unlock RPRX Revenue

PE Ratio Range

RPRX PE Ratio Range Unlock RPRX Revenue

Dividend Yield Range

RPRX Dividend Yield Range Unlock RPRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RPRX EPS Forecasts Unlock RPRX Revenue
Profile Summary

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
No. of Shareholders: n/a
No. of Employees: 35
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 607,106,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RPRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RPRX
Upcoming Events for RPRX
Frequently Asked Questions for Repros Therapeutics Inc
What is the Repros Therapeutics Inc share price?

As of 18/09/20, shares in Repros Therapeutics Inc are trading at $41.98, giving the company a market capitalisation of £19.73bn. This share price information is delayed by 15 minutes.

How has the Repros Therapeutics Inc share price performed this year?

Shares in Repros Therapeutics Inc are currently trading at $41.98 and the price has moved by 6.11k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Repros Therapeutics Inc price has moved by 5.43k% over the past year.

What are the analyst and broker recommendations for Repros Therapeutics Inc?

Of the analysts with advisory recommendations for Repros Therapeutics Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Repros Therapeutics Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Repros Therapeutics Inc next release its financial results?

Repros Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Repros Therapeutics Inc dividend yield?

Repros Therapeutics Inc does not currently pay a dividend.

Does Repros Therapeutics Inc pay a dividend?

Repros Therapeutics Inc does not currently pay a dividend.

When does Repros Therapeutics Inc next pay dividends?

Repros Therapeutics Inc does not currently pay a dividend.

How do I buy Repros Therapeutics Inc shares?

To buy shares in Repros Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Repros Therapeutics Inc?

Shares in Repros Therapeutics Inc are currently trading at $41.98, giving the company a market capitalisation of £19.73bn.

Where are Repros Therapeutics Inc shares listed? Where are Repros Therapeutics Inc shares listed?

Here are the trading details for Repros Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: RPRX
What kind of share is Repros Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Repros Therapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Repros Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Repros Therapeutics Inc.

How can I tell whether the Repros Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Repros Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 4.04k%. At the current price of $41.98, shares in Repros Therapeutics Inc are trading at 0.178k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Repros Therapeutics Inc PE Ratio?

The Repros Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 13.25. The shares are currently trading at $41.98.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Repros Therapeutics Inc?

Repros Therapeutics Inc's management team is headed by:

Pablo Legorreta - CHM
Terrance Coyne - CFO
Christopher Hite - VCH
George Lloyd - EVP
James Reddoch - EVP
Errol De Souza - IND
M. Germano Giuliani - DRC
Rory Riggs - DRC
Molly Chiaramonte - SVP
Marshall Urist - SVP
Bonnie Bassler - DRC
Catherine Engelber - IND
Who are the major shareholders of Repros Therapeutics Inc?

Here are the top five shareholders of Repros Therapeutics Inc based on the size of their shareholding:

Similar to RPRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.